Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)
Reactogenicity, the occurrence of vaccine side effects, can impact vaccine acceptance. There is limited data comparing the reactogenicity of COVID-19 vaccines to other routinely used vaccines, such as the meningococcal conjugate vaccine (MenACWY). In a trial of UK adults, participants received a third COVID-19 vaccine dose (NVX-CoV2373, BNT162b2, or mRNA1273) alongside MenACWY as an active control. Compared to MenACWY, we found that mRNA vaccines, particularly mRNA1273, showed the greatest relative increase in side effects, while protein-based NVX-CoV2373 generally elicited similar reactogenicity to MenACWY. These findings suggest that platform type can influence vaccine reactogenicity, and further research is needed to compare COVID-19 vaccines with other routinely administered vaccines.
COVID-19, MenACWY, Meningococcus, Reactogenicity, Vaccine
Marchese, Anthony M.
21a3aca4-c568-4aff-bc8e-7559e44c3065
Beyhaghi, Hadi
edb7ea56-4d4b-414e-834b-0884a1f94902
Rousculp, Matthew D.
35103c1c-7a47-4847-808e-948cb83ec000
Huang, Vivian
73a915ea-74b6-47da-a120-bd99bc454345
Liu, Xinxue
9167ef53-49a2-4100-a050-87569421468f
Toback, Seth
79fb869c-0e77-40be-838b-4510649f2865
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
16 December 2024
Marchese, Anthony M.
21a3aca4-c568-4aff-bc8e-7559e44c3065
Beyhaghi, Hadi
edb7ea56-4d4b-414e-834b-0884a1f94902
Rousculp, Matthew D.
35103c1c-7a47-4847-808e-948cb83ec000
Huang, Vivian
73a915ea-74b6-47da-a120-bd99bc454345
Liu, Xinxue
9167ef53-49a2-4100-a050-87569421468f
Toback, Seth
79fb869c-0e77-40be-838b-4510649f2865
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
Marchese, Anthony M., Beyhaghi, Hadi, Rousculp, Matthew D., Huang, Vivian, Liu, Xinxue, Toback, Seth and Faust, Saul N.
(2024)
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).
Vaccine, 44, [126569].
(doi:10.1016/j.vaccine.2024.126569).
Abstract
Reactogenicity, the occurrence of vaccine side effects, can impact vaccine acceptance. There is limited data comparing the reactogenicity of COVID-19 vaccines to other routinely used vaccines, such as the meningococcal conjugate vaccine (MenACWY). In a trial of UK adults, participants received a third COVID-19 vaccine dose (NVX-CoV2373, BNT162b2, or mRNA1273) alongside MenACWY as an active control. Compared to MenACWY, we found that mRNA vaccines, particularly mRNA1273, showed the greatest relative increase in side effects, while protein-based NVX-CoV2373 generally elicited similar reactogenicity to MenACWY. These findings suggest that platform type can influence vaccine reactogenicity, and further research is needed to compare COVID-19 vaccines with other routinely administered vaccines.
Text
1-s2.0-S0264410X24012519-main
- Version of Record
More information
Accepted/In Press date: 23 November 2024
e-pub ahead of print date: 5 December 2024
Published date: 16 December 2024
Keywords:
COVID-19, MenACWY, Meningococcus, Reactogenicity, Vaccine
Identifiers
Local EPrints ID: 496898
URI: http://eprints.soton.ac.uk/id/eprint/496898
ISSN: 0264-410X
PURE UUID: 1fc1eb4c-2a47-4a7d-b90d-92da12da164a
Catalogue record
Date deposited: 08 Jan 2025 12:36
Last modified: 22 Aug 2025 01:56
Export record
Altmetrics
Contributors
Author:
Anthony M. Marchese
Author:
Hadi Beyhaghi
Author:
Matthew D. Rousculp
Author:
Vivian Huang
Author:
Xinxue Liu
Author:
Seth Toback
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
